Valuation: Arcus Biosciences, Inc.

Market Cap 353.05Cr 309.66Cr 286.8Cr 263.89Cr 499.13Cr 34TCr 508.84Cr 3.42TCr 1.34TCr 17TCr 1.33TCr 1.3TCr 57TCr P/E 2026 *
-7.64x
P/E 2027 * -8.32x
Enterprise Value 290.91Cr 255.16Cr 236.33Cr 217.45Cr 411.29Cr 28TCr 419.29Cr 2.82TCr 1.1TCr 14TCr 1.09TCr 1.07TCr 47TCr EV / Sales 2026 *
34.2x
EV / Sales 2027 * 35.2x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day+1.19%
1 week-6.66%
Current month-8.42%
1 month+16.77%
3 months+22.71%
6 months+14.96%
Current year+18.49%
1 week 27.21
Extreme 27.21
30.86
1 month 23.31
Extreme 23.31
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.84
Extreme 8.84
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
24/06Sell

Founder

-6,431 0.0051%
11/06Free

Director

22,600 0.0180%
11/06Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+1.19%-6.66%+192.59%+28.93% 353.05Cr
-1.05%+1.39%+3.15%+6.98% 5.06TCr
+0.32%-3.29%+380.06%+590.92% 3.91TCr
-0.69%-1.23%+28.43%-6.98% 3.46TCr
+0.82%-1.36%+20.87%+55.23% 3.38TCr
-1.31%-1.76%+1.59%+27.01% 2.69TCr
+0.78%-0.14% - - 1.65TCr
+0.96%-2.17%+66.82%+119.74% 1.51TCr
-0.72%+0.12%+14.69%+16.95% 1.38TCr
+0.57%-1.48%+11.18%-32.50% 1.27TCr
Average +0.09%-2.03%+79.93%+89.59% 2.47TCr
Weighted average by Cap. -0.17%-1.22%+81.61%+119.64%

Financials

2026 *2027 *
Net sales 8.51Cr 7.46Cr 6.91Cr 6.36Cr 12Cr 814.14Cr 12Cr 82Cr 32Cr 399.81Cr 32Cr 31Cr 1.38TCr 9.31Cr 8.16Cr 7.56Cr 6.96Cr 13Cr 890.67Cr 13Cr 90Cr 35Cr 437.39Cr 35Cr 34Cr 1.51TCr
Net income -46Cr -40Cr -37Cr -34Cr -65Cr -4.37TCr -66Cr -441.87Cr -173.3Cr -2.15TCr -171.37Cr -167.63Cr -7.41TCr -43Cr -38Cr -35Cr -32Cr -61Cr -4.12TCr -62Cr -416.85Cr -163.49Cr -2.02TCr -161.67Cr -158.13Cr -6.99TCr
Net Debt -62Cr -54Cr -50Cr -46Cr -88Cr -5.95TCr -90Cr -601.58Cr -235.94Cr -2.92TCr -233.32Cr -228.22Cr -10TCr -26Cr -23Cr -21Cr -19Cr -37Cr -2.48TCr -37Cr -251.1Cr -98Cr -1.22TCr -97Cr -95Cr -4.21TCr
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
14/26/14 $28.30 +0.80% 1,33,086
13/26/13 $28.07 -2.94% 9,54,774
10/26/10 $28.92 -3.47% 8,11,732
09/26/09 $29.96 -0.99% 7,53,380
08/26/08 $30.26 +0.03% 11,35,939
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.07USD
Average target price
35.75USD
Spread / Average Target
+27.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock